CRISPR platform, biochemistry & cell biology related service and EGFR-related in vivo models

Dear ,

In the current issue of the OncoWuXi Newsletter, we share with you the update on our service and newly established capabilities.

OncoWuXi Newsletter will continue to keep you up to date with our recent progress in cancer research. As a part of the WuXi AppTec Research Service Division (RSD), our top-notch Oncology-Immunology team is dedicated to providing end-to-end services and solutions to support the ever-changing research needs of cancer and autoimmune diseases, and is your ideal partner for enabling technological breakthrough and accelerating cancer drug discovery.

CRISPR Platform

Integrated Target Identification and Validation Platform

(1) Cell line engineering and profiling

Generation of cell lines with inducible gene overexpression or knockdown via lentiviral system
Knockout via transient transfection of the CRISPR/Cas9 system, followed by 2D colony formation assay or drug response profiling
Knockout via lentiviral CRISPR/Cas9 system
Introduction of gene mutation or endogenous tagging with CRISPR RNP complexes or CRISPaint

(2) In vitro CRISPR screen

Positive screen or negative selection screen to identify mechanism of drug resistance or essential genes
Synthetic lethal screen
Cancer cell and T cell co-culture screen to identify regulators of cancer cell response to T cell cytotoxicity

(3) In vivo CRISPR screen

In vivo CRISPR screen for cancer immunotherapy modulators in syngeneic tumor models
Case study: an in vivo CRISPR screen with a library derived from tumor evolution under immune selection identified a gene required for PD-1 independent T cell cytotoxicity

In Vitro Platform

Biochemistry and Cell Biology Related Service

(1) Kinase assays

(2) Thermal shift assay

(3) Nucleotide exchange assay

(4) Cell viability or proliferation assays

(5) Tumor chemo-sensitivity assay (TCA)

(6) In vitro angiogenesis assay

(7) Transwell migration assay

(8) Soft agar colony formation assay

(9) Cell cycle, cell apoptosis and pyroptosis analysis

(10) Cell line construction

Targeted Oncology

EGFR-related In Vivo Models

(1) 7 EGFR-related CDX models of lung cancer and skin cancer, tested with Gefitinib, Osimertinib, Afatinib, Cetuximab, Icotinib, CO-1686, Erlotinib, or Panitumumab

(2) 15 acquired EGFR TKI (including Erlotinib, Afatinib, and Osimertinib)-resistant lung cancer PDX models

(3) 10 EGFR TKI (including Erlotinib, Gefitinib, Afatinib, and Osimertinib)- or Cetuximab- sensitive lung cancer PDX models

We sincerely appreciate your interest, time and support, and would like to hear your feedback so that we can continuously improve our service. Please don't hesitate to email us if you have any questions, suggestions or concerns.

Best regards,

WuXi AppTec OncoWuXi Team